Crucell’s chief financial officer Leonard Kruimer will now chair the supervisory board of ProFibrix B.V., a company developing products that help stop bleeding (haemostasis) after surgery. Vic Schmitt, a senior executive at Baxter International will also join the board as an independent director. Alain Parthoens (Vesalius Biocapital), Dirk Kersten (Gilde Healthcare Partners) and Francesco De Rubertis (Index Ventures) will also hold seats on the board.
On the management side, Jan Ohrstrom has been appointed chief executive officer. Dr. Ohrstrom was an executive at ZymoGenetics before joining ProFibrix. Jaap Koopman, the company’s founding CEO, will now become chief scientific officer. This raft of personnel changes comes as a result of the successful closing of a series B follow-on financing.
Copyright 2011 Evernow Publishing Ltd